ISIN: BE0974260896-XBRU Updated at

Prev close
Open
Volume
52wk Range
Capitalization

ISIN: BE0974260896-XBRU Updated at

Prev close
Open
Volume
52wk Range
Capitalization

Latest financial news

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad to Present at Cowen and Company 37th Annual Health Care Conference

Celyad to Present at Cowen and Company 37th Annual Health Care Conference

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Celyad announces third quarter 2016 business update

Celyad announces third quarter 2016 business update

Discover all financial news

Celyad's financial reports and corporate presentation

Letter for shareholders

Letter for shareholders

Q3 2016 Business Update

Q3 2016 Business Update

Celyad's corporate presentation

Celyad's corporate presentation

Accéder à toutes nos informations réglementées en français

Financial Calendar

August 29, 2017

Half Year Results - H1 2017

November 17, 2017

Q3 2017 - Business Update

About Celyad

Developing breakthrough pioneering therapies for life-threatening diseases.

Celyad is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Our scientific approach is inspired by the natural mechanisms that are used by the body to fight disease.

Read more about Celyad

'

Want to see more?

Know more about our regulated information